Article
Biochemistry & Molecular Biology
Alok Mishra, Anshuman Srivastava, Ankit Pateriya, Manendra Singh Tomar, Anand Kumar Mishra, Ashutosh Shrivastava
Summary: Breast cancer is the most common cancer among females, and endocrine therapy for ER-positive breast cancer can result in acquired resistance. The metabolic state of cancer cells plays a crucial role in their susceptibility to chemotherapeutic drugs, and understanding metabolic pathway alterations in TAMR cancer may offer potential therapeutic strategies.
CHEMICO-BIOLOGICAL INTERACTIONS
(2021)
Article
Oncology
Takuji Iwase, Shigehira Saji, Kotaro Iijima, Kenji Higaki, Shoichiro Ohtani, Yasuyuki Sato, Yasuo Hozumi, Yoshie Hasegawa, Yasuhiro Yanagita, Hiroyuki Takei, Maki Tanaka, Hideji Masuoka, Masahiko Tanabe, Chiyomi Egawa, Yoshifumi Komoike, Toshitaka Nakamura, Hiroshi Ohtsu, Hirofumi Mukai
Summary: This study investigated the effects of extending the treatment with an aromatase inhibitor for 10 years on disease-free survival in postmenopausal hormone receptor-positive breast cancer patients. The results showed that extending the treatment with an aromatase inhibitor for an additional 5 years improved disease-free survival.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Milena Foerster, Valerie McCormack, Benjamin O. Anderson, Pauline Boucheron, Annelle Zietsman, Herbert Cubasch, Maureen Joffe, Angelica Anele, Shadrach Offiah, Moses Galukande, Groesbeck Parham, Leeya F. Pinder, Ophira Ginsburg, Joachim Schuez, Isabel dos-Santos-Silva, Eva J. Kantelhardt
Summary: This study examined the treatment initiation, guideline concordance, and abandonment in patients with non-metastatic breast cancer in sub-Saharan Africa, highlighting the need for improved treatment access and completion to prevent premature breast cancer deaths.
Article
Pharmacology & Pharmacy
Cheng Huang, Liangping Su, Yitian Chen, Sangqing Wu, Ruipu Sun, Qiuping Xu, Xiaoyi Qiu, Ciqiu Yang, Xiangzhan Kong, Hongquan Qin, Xinbao Zhao, Xue Jiang, Kun Wang, Yinghua Zhu, Ping-Pui Wong
Summary: Dysregulated sphingolipid metabolism contributes to ER+ breast cancer progression and therapeutic response. This study established sphingolipid metabolic enzyme CERK as a regulator of TAMR in breast cancer, demonstrating its role in tamoxifen resistance and tumor growth. Mechanistically, high CERK expression inhibits tamoxifen-induced sphingolipid ceramide accumulation, leading to tamoxifen resistance in TAMR cells. This work provides valuable insight into the regulation of sphingolipid metabolism and identifies a potential therapeutic target for tamoxifen resistance in breast cancer.
PHARMACOLOGICAL RESEARCH
(2023)
Article
Oncology
Binghe Xu, Huiping Li, Zefei Jiang, Lin Gu, Jinhai Tang, Hui Xie, Yueyin Pan, Yunjiang Liu, Shude Cui, Xiaojia Wang, Li Cai, Yiqiong Zhang, Huadong Zhao, Zhimin Shao
Summary: This study evaluated the efficacy and safety of exemestane in Chinese postmenopausal women with ER+ breast cancer who had previously received 2-3 years of tamoxifen treatment. The results showed a low event incidence rate and a good event-free survival probability over the total exposure time of exemestane therapy. Multivariate analysis revealed an association between tumor, lymph node, and metastasis stage at initial diagnosis and time to event. Most treatment-related adverse events were of mild to moderate severity. Overall, the study supports the efficacy and safety of exemestane in this population.
CHINESE JOURNAL OF CANCER RESEARCH
(2022)
Article
Oncology
Mina S. Sedrak, Can-Lan Sun, Jingran Ji, Harvey J. Cohen, Cary P. Gross, William P. Tew, Heidi D. Klepin, Tanya M. Wildes, Efrat Dotan, Rachel A. Freedman, Tracey O'Connor, Selina Chow, Mary Ann Fenton, Beverly Moy, Andrew E. Chapman, William Dale, Vani Katheria, Nicole M. Kuderer, Gary H. Lyman, Allison Magnuson, Hyman B. Muss
Summary: Older women with high-risk early breast cancer often suffer from toxic side effects during adjuvant chemotherapy, leading to dose reductions and delays. Identifying women at risk of receiving suboptimal dose intensity may improve treatment discussions and guide early supportive care interventions.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Min Yan, Peng Yuan, Quchang Ouyang, Ying Cheng, Guohui Han, Dewei Wang, Li Ran, Tao Sun, Da Zhao, Yuju Bai, Shun'e Yang, Xiaojia Wang, Rong Wu, Xiaohua Zeng, Herui Yao, Xuening Ji, Jun Jiang, Xiaohua Hu, Haifeng Lin, Liping Zheng, Zhitu Zhu, Wei Ge, Junlan Yang, Tongjian Cui, Xiaozhi Zhang, Fangyang Lu, Wenhui Li, Hongyan Xu, Mafei Kang, Ping Gong, Liqun Zou, Jiang Liu, Hongliang Zhang, Hao Yu, Binghe Xu
Summary: This study evaluated the efficacy and safety of lobaplatin-based chemotherapy in Chinese patients with metastatic breast cancer. The results showed that lobaplatin-based chemotherapy had favorable efficacy and manageable safety profile in advanced breast cancer patients.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Article
Surgery
Elisabeth Dupont, Theodore Tsangaris, Carlos Garcia-Cantu, Marissa Howard-McNatt, Akiko Chiba, Adam C. Berger, Edward A. Levine, Jennifer S. Gass, Kristalyn Gallagher, Sharon S. Lum, Ricardo D. Martinez, Alliric Willis, Sonali Pandya, Eric A. Brown, Andrew Fenton, Amanda Mendiola, Mary Murray, Naveenraj L. Solomon, Maheswari Senthil, David W. Ollila, David Edmonson, Melissa Lazar, Jukes P. Namm, Fangyong Li, Meghan Butler, Noreen E. McGowan, Maria E. Herrera, Yoana P. Avitan, Brian Yoder, Laura L. Walters, Tara McPartland, Anees B. Chagpar
Summary: This study demonstrates that resection of cavity shave margins (CSM) significantly reduces positive margin and re-excision rates in breast cancer patients undergoing partial mastectomy (PM).
Article
Oncology
Gerd Fastner, Roland Reitsamer, Christoph Gaisberger, Wolfgang Hitzl, Bartosz Urbanski, Dawid Murawa, Christiane Matuschek, Wilfried Budach, Antonella Ciabattoni, Juliann Reiland, Marie Molnar, Cristiana Vidali, Claudia Schumacher, Felix Sedlmayer
Summary: Intraoperative electron radiation therapy (IOERT) combined with moderate hypofractionation schedule has been shown to effectively reduce local recurrence rates in patients with invasive breast cancer after breast conserving surgery. The HIOB trial demonstrated low five-year local recurrence rates and minimal toxicity, making it a viable treatment option for these patients.
Article
Multidisciplinary Sciences
A. B. Sanchez-Spitman, J. J. Swen, V. O. Dezentje, D. J. A. R. Moes, H. Gelderblom, H. J. Guchelaar
Summary: The study found that CYP2C19 genotypes do not have a significant impact on tamoxifen metabolism or breast cancer relapse. However, significant differences were observed in tamoxifen activity groups, indicating a potential influence on metabolism.
SCIENTIFIC REPORTS
(2021)
Article
Health Care Sciences & Services
Thais Almeida, Werner Schroth, Jeanine Nardin, Thomas E. Murdter, Stefan Winter, Solane Picolotto, Reiner Hoppe, Jenifer Kogin, Elisa Gaio, Angela Dasenbrock, Raquel Cristina Skrsypcsak, Lucia de Noronha, Matthias Schwab, Hiltrud Brauch, Jose Claudio Casali-da-Rocha
Summary: This study investigated the association between the active tamoxifen metabolite (Z)-endoxifen and event-free survival in early-stage breast cancer patients, and found that lower levels of (Z)-endoxifen were associated with shorter survival.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Oncology
C. Louwrens Braal, Justin D. Westenberg, Sanne M. Buijs, Steven Abrams, Tessa A. M. Mulder, Ron H. N. van Schaik, Stijn L. W. Koolen, Agnes Jager, Ron H. J. Mathijssen
Summary: This study aimed to identify factors that determine the inter-individual variability in endoxifen concentration, the principal metabolite of tamoxifen. The results showed that CYP2D6 genotype, age, and weight were key predictors of endoxifen concentration. Additionally, CYP2D6 genotype and age were found to be predictors of the risk for subtherapeutic endoxifen concentrations. The study highlights the importance of individualized tamoxifen treatment and therapeutic drug monitoring.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Karolina Edlund, Katrin Madjar, Antje Lebrecht, Bahriye Aktas, Henryk Pilch, Gerald Hoffmann, Manfred Hofmann, Hans-Christian Kolberg, Daniel Boehm, Marco Battista, Martina Seehase, Kathrin Stewen, Susanne Gebhard, Cristina Cadenas, Rosemarie Marchan, Walburgis Brenner, Annette Hasenburg, Heinz Koelbl, Christine Solbach, Mathias Gehrmann, Berno Tanner, Karsten E. Weber, Sibylle Loibl, Agapios Sachinidis, Joerg Rahnenfuehrer, Marcus Schmidt, Jan G. Hengstler
Summary: An expression-based classifier was developed and validated to predict pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT), showing good accuracy, AUC, and NPV. The classifier was particularly effective in identifying patients who do not achieve a pCR in about one third of luminal breast cancers.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Stefan A. J. Buck, C. Louwrens Braal, Maaike M. Hofman, Esther Oomen-de Hoop, Peter de Bruijn, Inge M. Ghobadi Moghaddam-Helmantel, Koen G. A. M. Hussaarts, Mijntje B. Vastbinder, Quirine C. Van Rossum-Schornagel, Ron H. N. van Schaik, Agnes Jager, Stijn L. W. Koolen, Ron H. J. Mathijssen
Summary: Combining probenecid with tamoxifen can effectively increase the concentration of endoxifen in breast cancer patients, providing a solution for patients who have poor metabolism or low endoxifen concentrations despite earlier tamoxifen treatment.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Article
Oncology
Andrea DeCensi, Harriet Johansson, Thomas Helland, Matteo Puntoni, Debora Macis, Valentina Aristarco, Silvia Caviglia, Tania Buttiron Webber, Irene Maria Briata, Mauro D'Amico, Davide Serrano, Aliana Guerrieri-Gonzaga, Ersilia Bifulco, Steinar Hustad, Havard Soiland, Luca Boni, Bernardo Bonanni, Gunnar Mellgren
Summary: Low-dose tamoxifen can reduce the risk of recurrence in non-invasive breast cancer by half without significant adverse events. Most subjects treated with 5 mg/day have endoxifen levels below 9 nM, and there is no significant association with recurrence, indicating that tamoxifen failure is not related to poor drug metabolism.
Article
Medicine, General & Internal
David J. McLernon, Daniele Giardiello, Ben Van Calster, Laure Wynants, Nan van Geloven, Maarten van Smeden, Terry Therneau, Ewout W. Steyerberg, STRATOS Initiative
Summary: Risk prediction models need validation to assess their performance. This article focuses on evaluating predictions and improving clinical decision making using survival models based on Cox proportional hazards regression. The authors present a case study on breast cancer patients, where a Cox regression model is developed and validated for prediction of recurrence or death.
ANNALS OF INTERNAL MEDICINE
(2023)
Article
Health Care Sciences & Services
Alexander Pate, Richard D. Riley, Gary S. Collins, Maarten van Smeden, Ben Van Calster, Joie Ensor, Glen P. Martin
Summary: Multinomial logistic regression models are used to predict the risk of a categorical outcome with more than two categories. Researchers need to ensure that the number of participants is appropriate relative to the number of events and predictor variables for each category. This study proposes three criteria to determine the minimum required sample size, aiming to minimize overfitting, difference between observed and adjusted R-2 Nagelkerke, and ensure accurate estimation of overall risk. The criteria were evaluated through simulation study and applied to a worked example, with code provided for implementation in R and Stata.
STATISTICAL METHODS IN MEDICAL RESEARCH
(2023)
Review
Health Care Sciences & Services
Paula Dhiman, Jie Ma, Constanza L. Andaur Navarro, Benjamin Speich, Garrett Bullock, Johanna A. A. Damen, Lotty Hooft, Shona Kirtley, Richard D. Riley, Ben Van Calster, Karel G. M. Moons, Gary S. Collins
Summary: This article conducted a systematic review on oncology-related studies that developed and validated prognostic models using machine learning. The findings revealed the presence of spin, i.e., overinterpretation of findings, in these studies. The inconsistent reporting and use of overly strong or leading words in the publications indicate the need for caution when reading and using prognostic models in oncology.
JOURNAL OF CLINICAL EPIDEMIOLOGY
(2023)
Article
Oncology
Archita Biswas, Manuela Salvucci, Kate Connor, Heiko Dussmann, Steven Carberry, Michael Fichtner, Ellen King, Brona Murphy, Alice C. O'Farrell, Jane Cryan, Alan Beausang, Josephine Heffernan, Mattia Cremona, Bryan T. Hennessy, James Clerkin, Kieron J. Sweeney, Steve MacNally, Francesca Brett, Philip O'Halloran, Orna Bacon, Simon Furney, Maite Verreault, Emie Quissac, Franck Bielle, Mohammed H. Ahmed, Ahmed Idbaih, Sieger Leenstra, Ioannis Ntafoulis, Federica Fabro, Martine Lamfers, Anna Golebiewska, Frank Hertel, Simone P. Niclou, Romain Tching Chi Yen, Andreas Kremer, Gonca Dilcan, Francesca Lodi, Ingrid Arijs, Diether Lambrechts, Manasa Kalya Purushothama, Alexander Kel, Annette T. Byrne, Jochen H. M. Prehn
Summary: This study investigated molecular differences between long-term survivors (LTS) and short-term survivors (STS) of glioblastoma (GBM). Cilium gene signatures were found to be enriched in LTS tumors, while STS tumors exhibited abnormal protein expression. These findings provide potential biomarkers and therapeutic targets for the management of GBM.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Letter
Multidisciplinary Sciences
Ben Van Calster
Article
Oncology
Liselore Loverix, Ignace Vergote, Pieter Busschaert, Adriaan Vanderstichele, Tom Venken, Bram Boeckx, Philipp Harter, Hilde Brems, Els Van Nieuwenhuysen, Sandro Pignata, Thais Baert, Antonio Gonzalez-Martin, Sileny Han, Christian Marth, Patrick Neven, Nicoletta Colombo, Patrick Berteloot, Johanna Maeenpaeae, Siel Olbrecht, Tina Laga, Erwin Sablon, Isabelle Ray-Coquard, Eric Pujade-Lauraine, Diether Lambrechts, Toon Van Gorp
Summary: The Leuven HRD test and Myriad HRD test have similar predictive value for PFS and OS in HRD+ patients, and there is a robust correlation between the two tests.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Federica Fabro, Trisha V. Kers, Kate J. Feller, Cecile Beerens, Ioannis Ntafoulis, Ahmed Idbaih, Maite Verreault, Kate Connor, Archita Biswas, Manuela Salvucci, Jochen H. M. Prehn, Annette T. Byrne, Alice C. O'Farrell, Diether Lambrechts, Gonca Dilcan, Francesca Lodi, Ingrid Arijs, Andreas Kremer, Romain Tching Chi Yen, Miao-Ping Chien, Martine L. M. Lamfers, Sieger Leenstra
Summary: Chemotherapy using temozolomide is the standard treatment for glioblastoma, but temozolomide resistance remains a challenge. This study reveals the association between resistance and heterogeneity in glioblastoma, and identifies distinct phenotypic behaviors and gene expressions in response to temozolomide. The adaptability and heterogeneity of glioblastoma cells contribute to their ability to survive and develop resistance mechanisms.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Health Care Sciences & Services
Shan Gao, Elena Albu, Krizia Tuand, Veerle Cossey, Frank Rademakers, Ben Van Calster, Laure Wynants
Summary: This systematic review assessed the risk of bias and applicability of published prediction models for central line-associated bloodstream infection (CLA-BSI) in hospitalized patients. The results revealed a lack of prediction models with potential clinical use and highlighted the urgent need for the development of an applicable model for CLA-BSI.
JOURNAL OF CLINICAL EPIDEMIOLOGY
(2023)
Article
Genetics & Heredity
Hagai Levi, Shai Carmi, Saharon Rosset, Rinat Yerushalmi, Aviad Zick, Tamar Yablonski-Peretz, Qin Wang, Manjeet K. Bolla, Joe Dennis, Kyriaki Michailidou, Michael Lush, Thomas Ahearn, Irene L. Andrulis, Hoda Anton-Culver, Antonis C. Antoniou, Volker Arndt, Annelie Augustinsson, Paivi Auvinen, Laura Beane Freeman, Matthias Beckmann, Sabine Behrens, Marina Bermisheva, Clara Bodelon, Natalia Bogdanova, Stig E. Bojesen, Hermann Brenner, Helen Byers, Nicola Camp, Jose Castelao, Jenny Chang-Claude, Maria-Dolores Chirlaque, Wendy Chung, Christine Clarke, Margriet J. Collee, Sarah Colonna, Fergus Couch, Angela Cox, Simon S. Cross, Kamila Czene, Mary Daly, Peter Devilee, Thilo Dork, Laure Dossus, Diana M. Eccles, A. Heather Eliassen, Mikael Eriksson, Gareth Evans, Peter Fasching, Olivia Fletcher, Henrik Flyger, Lin Fritschi, Marike Gabrielson, Manuela Gago-Dominguez, Montserrat Garcia-Closas, Jose Angel Garcia-Saenz, Jeanine Genkinger, Graham G. Giles, Mark Goldberg, Pascal Guenel, Per Hall, Ute Hamann, Wei He, Peter Hillemanns, Antoinette Hollestelle, Reiner Hoppe, John Hopper, Simona Jakovchevska, Anna Jakubowska, Helena Jernstrom, Esther John, Nichola Johnson, Michael Jones, Joseph Vijai, Rudolf Kaaks, Elza Khusnutdinova, Cari Kitahara, Stella Koutros, Vessela Kristensen, Allison W. Kurian, James Lacey, Diether Lambrechts, Loic Le Marchand, Flavio Lejbkowicz, Annika Lindblom, Sibylle Loibl, Adriana Lori, Jan Lubinski, Arto Mannermaa, Mehdi Manoochehri, Dimitrios Mavroudis, Usha Menon, AnnaMarie Mulligan, Rachel Murphy, Ines Nevelsteen, William G. Newman, Nadia Obi, Katie O'Brien, Ken Offit, Andrew Olshan, Dijana Plaseska-Karanfilska, Janet Olson, Salvatore Panico, Tjoung-Won Park-Simon, Alpa Patel, Paolo Peterlongo, Brigitte Rack, Paolo Radice, Gad Rennert, Valerie Rhenius, Atocha Romero, Emmanouil Saloustros, Dale Sandler, Marjanka K. Schmidt, Lukas Schwentner, Mitul Shah, Priyanka Sharma, Jacques Simard, Melissa Southey, Jennifer Stone, William J. Tapper, Jack Taylor, Lauren Teras, Amanda E. Toland, Melissa Troester, Therese Truong, Lizet E. van der Kolk, Clarice Weinberg, Camilla Wendt, Xiaohong Rose Yang, Wei Zheng, Argyrios Ziogas, Alison M. Dunning, Paul Pharoah, Douglas F. Easton, Shay Ben-Sachar, Naama Elefant, Ron Shamir, Ran Elkon
Summary: This study examined the performance of European-based breast cancer (BC) polygenic risk score (PRS) models in Ashkenazi Jewish (AJ) women. The results showed that the European-based PRS models can identify AJ women with significantly increased BC risk, offering potential improvement in BC risk assessment for this population.
JOURNAL OF MEDICAL GENETICS
(2023)
Article
Oncology
Ioannis Ntafoulis, Anne Kleijn, Jie Ju, Kevin Jimenez-Cowell, Federica Fabro, Michelle Klein, Romain Tching Chi Yen, Rutger K. Balvers, Yunlei Li, Andrew P. Stubbs, Trisha V. Kers, Johan M. Kros, Sean E. Lawler, Laurens V. Beerepoot, Andreas Kremer, Ahmed Idbaih, Maite Verreault, Annette T. Byrne, Alice C. O'Farrell, Kate Connor, Archita Biswas, Manuela Salvucci, Jochen H. M. Prehn, Diether Lambrechts, Gonca Dilcan, Francesca Lodi, Ingrid Arijs, Martin J. van den Bent, Clemens M. F. Dirven, Sieger Leenstra, Martine L. M. GLIOTRAIN Consortium, Martine L. M. Lamfers
Summary: The study revealed that patient-derived glioma stem-like cells (GSCs) retain gene expressions similar to their corresponding DNA and RNA sequences despite the loss of their natural environment. GSCs were found to predict patient response to treatment more accurately and transcriptome analysis identified potential biomarkers for this response. This study demonstrates that GSCs provide a tool to improve glioblastoma drug development and precision medicine.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Pooja K. Middha, Xiaoliang Wang, Sabine Behrens, Manjeet K. Bolla, Qin Wang, Joe Dennis, Kyriaki Michailidou, Thomas U. Ahearn, Irene L. Andrulis, Hoda Anton-Culver, Volker Arndt, Kristan J. Aronson, Paul L. Auer, Annelie Augustinsson, Thais Baert, Laura E. Beane Freeman, Heiko Becher, Matthias W. Beckmann, Javier Benitez, Stig E. Bojesen, Hiltrud Brauch, Hermann Brenner, Angela Brooks-Wilson, Daniele Campa, Federico Canzian, Angel Carracedo, Jose E. Castelao, Stephen J. Chanock, Georgia Chenevix-Trench, Emilie Cordina-Duverger, Fergus J. Couch, Angela Cox, Simon S. Cross, Kamila Czene, Laure Dossus, Pierre-Antoine Dugue, A. Heather Eliassen, Mikael Eriksson, D. Gareth Evans, Peter A. Fasching, Jonine Figueroa, Olivia Fletcher, Henrik Flyger, Marike Gabrielson, Manuela Gago-Dominguez, Graham G. Giles, Anna Gonzalez-Neira, Felix Grassmann, Anne Grundy, Pascal Guenel, Christopher A. Haiman, Niclas Hakansson, Per Hall, Ute Hamann, Susan E. Hankinson, Elaine F. Harkness, Bernd Holleczek, Reiner Hoppe, John L. Hopper, Richard S. Houlston, Anthony Howell, David J. Hunter, Christian Ingvar, Karolin Isaksson, Helena Jernstroem, Esther M. John, Michael E. Jones, Rudolf Kaaks, Renske Keeman, Cari M. Kitahara, Yon-Dschun Ko, Stella Koutros, Allison W. Kurian, James V. Lacey, Diether Lambrechts, Nicole L. Larson, Susanna Larsson, Loic Le Marchand, Flavio Lejbkowicz, Shuai Li, Martha Linet, Jolanta Lissowska, Maria Elena Martinez, Tabea Maurer, Anna Marie Mulligan, Claire Mulot, Rachel A. Murphy, William G. Newman, Sune F. Nielsen, Borge G. Nordestgaard, Aaron Norman, Katie M. O'Brien, Janet E. Olson, Alpa V. Patel, Ross Prentice, Erika Rees-Punia, Gad Rennert, Valerie Rhenius, Kathryn J. Ruddy, Dale P. Sandler, Christopher G. Scott, Mitul T. Shah, Xiao-Ou Shu, Ann Smeets, Melissa C. Southey, Jennifer Stone, Rulla M. Tamimi, Jack A. Taylor, Lauren R. Teras, Katarzyna Tomczyk, Melissa A. Troester, Therese Truong, Celine M. Vachon, Sophia S. Wang, Clarice R. Weinberg, Hans Wildiers, Walter Willett, Stacey J. Winham, Alicja Wolk, Xiaohong Yang, M. Pilar Zamora, Wei Zheng, Argyrios Ziogas, Alison M. Dunning, Paul D. P. Pharoah, Montserrat Garcia-Closas, Marjanka K. Schmidt, Peter Kraft, Roger L. Milne, Sara Lindstroem, Douglas F. Easton, Jenny Chang-Claude
Summary: A genome-wide study identified two independent SNP-risk factor pairs associated with breast cancer risk and estrogen receptor positive (ER +) breast cancer risk. Overall, gene-environment interactions have a very small contribution to the heritability of breast cancer. At the population level, these interactions do not significantly contribute to risk prediction for breast cancer.
BREAST CANCER RESEARCH
(2023)
Article
Oncology
Szymon Macioszek, Danuta Dudzik, Rafal Bartoszewski, Tomasz Stokowy, Diether Lambrechts, Bram Boeckx, Agnieszka Wozniak, Patrick Schoffski, Michal J. Markuszewski
Summary: In this study, integrative metabolomic and transcriptomic analyses were performed to investigate the impact of imatinib treatment on tumour biochemical processes. The results revealed differential metabolite and gene expression profiles, indicating changes in pruine and pyrinridine metabolism, butanoate metabolism, as well as alanine, aspartate, and glutamate metabolism. These findings provide insights into the mechanisms of imatinib's anti-tumour activity and suggest a potentially novel approach for enhancing its efficacy or re-sensitizing imatinib-resistant tumours.
TRANSLATIONAL ONCOLOGY
(2023)
Article
Medicine, Research & Experimental
Jelle Verhoeven, Kathryn A. Jacobs, Francesca Rizzollo, Francesca Lodi, Yichao Hua, Joanna Pozniak, Adhithya Narayanan Srinivasan, Diede Houbaert, Gautam Shankar, Sanket More, Marco B. Schaaf, Nikolina Dubroja Lakic, Maarten Ganne, Jochen Lamote, Johan Van Weyenbergh, Louis Boon, Oliver Bechter, Francesca Bosisio, Yasuo Uchiyama, Mathieu J. M. Bertrand, Jean Christophe Marine, Diether Lambrechts, Gabriele Bergers, Madhur Agrawal, Patrizia Agostinis
Summary: Autophagy in tumor endothelial cells plays a role in suppressing inflammatory responses and maintaining immunosuppression. The loss of autophagy in TECs enhances antitumor immunity by promoting infiltration and function of T-cells. The presence of an inflammatory TEC phenotype correlates with clinical responses to immunotherapy.
EMBO MOLECULAR MEDICINE
(2023)
Meeting Abstract
Oncology
Manuela Salvucci, Liam Poynter, Reza Mirnezami, Steven Carberry, Robert O'Byrne, James Alexander, Diether Lambrechts, Kirill Veselkov, James M. Kinross, Jochen Prehn
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Ha-Linh Nguyen, Tatjana Geukens, Marion Maetens, Samuel Aparicio, Ayse Bassez, Ake Borg, Jane Brock, Annegien Broeks, Carlos Caldas, Fatima Cardoso, Maxim De Schepper, Mauro Delorenzi, Caroline A. Drukker, Annuska M. Glas, Andrew R. Green, Edoardo Isnaldi, Jorunn Eyfjoro, Hazem Khout, Stian Knappskog, Savitri Krishnamurthy, Sunil R. Lakhani, Anita Langerod, John W. M. Martens, Amy E. McCart Reed, Leigh Murphy, Stefan Naulaerts, Serena Nik-Zainal, Ines Nevelsteen, Patrick Neven, Martine Piccart, Coralie Poncet, Kevin Punie, Colin Purdie, Emad A. Rakha, Andrea Richardson, Emiel Rutgers, Anne Vincent-Salomon, Peter T. Simpson, Marjanka K. Schmidt, Christos Sotiriou, Paul N. Span, Kiat Tee Benita Tan, Alastair Thompson, Stefania Tommasi, Karen Van Baelen, Marc Van de Vijver, Steven Van Laere, Laura van't Veer, Giuseppe Viale, Alain Viari, Hanne Vos, Anke T. Witteveen, Hans Wildiers, Giuseppe Floris, Abhishek D. Garg, Ann Smeets, Diether Lambrechts, Elia Biganzoli, Francois Richard, Christine Desmedt
Summary: Obesity is associated with an increased risk of developing breast cancer and worse prognosis in breast cancer patients. This study investigates the biological differences in untreated primary breast cancer according to patients' body mass index (BMI). The study finds several genomic alterations that are differentially prevalent in overweight or obese patients compared to lean patients. It also reveals an elevated and unresolved inflammation of the breast cancer tumor microenvironment associated with obesity. The findings suggest that patient adiposity may play a significant role in the heterogeneity of breast cancer and should be considered for tailored treatment.
NATURE COMMUNICATIONS
(2023)
